Has Rachel Miest, MD received payments from drug or device companies?

Yes. Drug and device makers reported $227 in general payments to Rachel Miest, MD across 11 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rachel Miest, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rachel Miest, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rachel Miest, MD

Dermatology · Rochester, MNNPI 1285920603

Payments from drug & device makers

$227in general payments, 2019–2025

Across 11 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$94
Amgen$35
LEO Pharma Inc.$27
Lilly USA, LLC$27
Sun Pharmaceutical Industries Inc.$16
E.r. Squibb & Sons, L.L.C.$15
plus $14 from 1 others

What the payments were for

Food & beverage$21293%
Education$157%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	4	$94
Amgen	2	$35
LEO Pharma Inc.	1	$27
Lilly USA, LLC	1	$27
Sun Pharmaceutical Industries Inc.	1	$16
E.r. Squibb & Sons, L.L.C.	1	$15
Smith+Nephew	1	$14

How this compares

$227 in reported general payments places this provider in the 50th percentile of 273 dermatology providers in Minnesota.

See all dermatology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$75,308

Medicare patients

284

Services billed

1,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ketoconazole	130	$2,364
Tacrolimus	19	$2,139
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc	32	$1,132
Fluocinonide	30	$971
Triamcinolone Acetonide	76	$760
Fluconazole	14	$589
Clindamycin Phosphate	12	$319
Hydrocortisone	62	$306
Hydroxyzine Hcl	16	$288
Finasteride	13	$217
Doxycycline Monohydrate	13	$197
ValacyclovirValacyclovir Hcl	19	$172
Doxycycline Hyclate	12	$148
Terbinafine Hcl	14	$141
Mupirocin	16	$109

Paid to pharmacies, not to this prescriber.

Other dermatology in Rochester

Afsaneh AlaviRochester$440K
Michael CamilleriRochester$297K
Megha TollefsonRochester$243K
Michael WangRochester$75K
Julio Sartori-ValinottiRochester$44K
Saranya WylesRochester$40K
Julia LehmanRochester$15K
Nessa Aghazadeh MohandesiRochester$11K
Alina BridgesRochester$11K
Jennifer MartinRochester$3K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →